

Amendments to the Specification:

Please replace existing paragraph [0009] with the following:

[0009] The tumor seeking molecule is preferably a biomolecule, such as a peptide or protein that is actively targeted to the tumor cell. Examples of these biomolecules are somatostatin-, neurotensin-, bombesin-receptor binding molecules, monoclonal antibodies, PenetratinTM peptides, antennapedia peptides, e.g., PENETRATIN®, and glycoproteins, and molecules binding to the GPIIb/IIIa receptors. PENETRATIN® is manufactured by Cyclacel Limited, having a place of business at 5 Whitehall Crescent Dundee, Scotland DD1 4AR, United Kingdom. The invention is however not limited to these examples and is more generally applicable to other tumor seeking agents as well. This category encompasses in addition compounds which are known to be transported into the nucleus or the nucleus membrane. Examples of these are anti-sense oligonucleotides, proliferating agents, like deoxy-uridine, and small molecules, like spermidine. The intercalating moiety is preferably an aromatic molecule with an intercalative binding affinity for double-stranded DNA. Examples of such aromatic compounds are compounds containing i.e. acridine, porphyrin, ellipticine, phenantroline, carbazole, benzimidazole or compounds with known cytostatic activity (antibiotics) from the class of tetracyclines (anthracyclines), such as daunorubicine, epirubicine or mixoxantrone and are functionalized with ligands able to coordinate the $[M(CO)_3]^+$ moiety. Examples of such ligands are those mentioned in EP-879 606 and additionally polyamino-polycarboxylates, phosphates and phosphonates, aliphatic or aromatic or mixed triamines and thiones.